Latest Stock Buy or Sell?

Base metals could benefit from any trade war positive news and could see a $7-$8 move quickly, which would test resistance near $39. Seasonality is working against the base metals at the moment until October. He likes this as a good long term risk-reward, but it could potentially re-test the $22 range.

This is heading into the seasonal buy cycle and the stock is building a nice technical base. He expects to see this around $58 on the seasonal rally. It has a Central America partner that will add to its growth. He thinks investors are looking at this as a defensive holding. Yield 0.3%. (Analysts’ price target is $62.86)

He has taken a 10% weighting in this in the portfolio. He likes the technical basing and is expecting good news with the next earnings report in early August. Very good risk-reward and a good defensive holding. Yield 5.4%. (Analysts’ price target is $59.22)

He started buying in December and thinks the market has beaten the stock up over the Trump Administration move to curb pharmaceutical pricing. He thinks the market is underestimating sales growth. The sector is in a secular bull market. Yield 3.1%. (Analysts’ price target is $69.16)

(A Top Pick July 20/17 Down 4%) The gain has evaporated into a slight loss, but he sees this entering into a bullish seasonal cycle so will hold it. The risk-reward is very good right now. There could be take-out rumours soon as the big banks are purchasing such assets.

(A Top Pick July 20/17 Up 33%). He would keep buying this today. The company helps its customer’s business become more efficient. The long term up trend remains intact.

(A Top Pick July 20/17 Up 21%). It has been losing some value lately, but thinks the risk-reward near $13.50 looks good and this is a previous area of resistance back late last year. He expects to see a test again of $15.50 and would still suggest this as a buy at these levels on a technical basis.